ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 238 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,460,884 | -83.4% | 70,100 | -80.9% | 0.00% | -81.8% |
| Q2 2023 | $8,784,573 | +339.5% | 366,788 | +245.4% | 0.02% | +266.7% |
| Q1 2023 | $1,998,684 | +1027.3% | 106,200 | +853.6% | 0.01% | +500.0% |
| Q4 2022 | $177,301 | -78.6% | 11,137 | -81.1% | 0.00% | -66.7% |
| Q2 2022 | $828,000 | -85.8% | 58,800 | -75.5% | 0.00% | -82.4% |
| Q1 2022 | $5,824,000 | +856.3% | 240,471 | +821.3% | 0.02% | +1600.0% |
| Q4 2021 | $609,000 | +133.3% | 26,100 | +66.2% | 0.00% | 0.0% |
| Q3 2021 | $261,000 | -22.6% | 15,700 | +13.8% | 0.00% | 0.0% |
| Q2 2021 | $337,000 | -97.6% | 13,800 | -95.2% | 0.00% | -98.6% |
| Q2 2020 | $13,892,000 | +354.3% | 286,618 | +301.0% | 0.07% | +666.7% |
| Q4 2019 | $3,058,000 | -59.4% | 71,480 | -65.9% | 0.01% | -64.0% |
| Q3 2019 | $7,540,000 | +42.0% | 209,496 | +5.5% | 0.02% | +38.9% |
| Q2 2019 | $5,309,000 | +24.9% | 198,623 | +34.8% | 0.02% | +12.5% |
| Q4 2016 | $4,250,000 | – | 147,339 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |